We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
MSCI Inc. (MSCI - Free Report) reported fourth-quarter 2019 adjusted earnings of $1.67 per share, which beat the Zacks Consensus Estimate by 2.5% and increased 27.5% from the year-ago quarter.
Operating revenues increased 12.4% year over year to $406.6 million, beating the consensus mark by 0.7%. The year-over-year growth was driven by an increase of 8.4% and 18.3% in recurring subscriptions (72.4% of revenues) and asset-based fees (23.7% of revenues), respectively.
Non-recurring revenues (3.9% of revenues) surged 83% year over year to $15.8 million. The solid growth was primarily driven by increased sales in BarraOne and RiskManager product offerings.
Organic operating revenues (excluding the impact of acquisitions, divestitures and foreign currency exchange rate fluctuations) rose 12.5% year over year.
Organic recurring subscription, asset-based fee and non-recurring revenues grew 8.5%, 18.3% and 82.3%, respectively.
At the end of the quarter, average assets under management (AUM) were $934.4 billion in ETFs linked to MSCI indexes. Total retention rate was 92.9% in the quarter.
In the fourth quarter, Index operating revenues (59.8% of operating revenues) improved 15.6% year over year to $243.2 million, primarily driven by strong growth in recurring subscriptions (up 11.5%) and asset-based fees (up 18.3%).
The increase in recurring subscriptions was driven by growth in factor and ESG index products, core developed market modules and index level products.
Index net new recurring subscription sales increased 14%.
Analytics Revenue Details
Analytics operating revenues (31.5% of operating revenues) improved 5.1% year over year to $128.2 million. While recurring subscription revenues increased 2.2%, non-recurring revenues jumped 162.5%. Multi-Asset Class Analytics products also witnessed growth in the quarter.
Analytics net new recurring subscription sales grew 50.1%.
All Other Segment Revenue Details
All Other operating revenues (8.7% of operating revenues) rose 20.1% from the year-ago quarter to $35.2 million, primarily driven by recurring subscriptions (up 20.8%).
All Other organic operating revenue growth was 19.9%, with ESG organic operating revenues increasing 29.8% and Real Estate organic operating revenues 1.3%.
All Other net new recurring subscription sales grew 33.7%.
Operating Details
Adjusted EBITDA grew 16% year over year to $220.2 million in the reported quarter. Moreover, adjusted EBITDA margin expanded 170 basis points (bps) on a year-over-year basis to 54.2%.
Total operating expenses increased 12.4% year over year to $406.6 million, primarily due to higher compensation and benefit costs.
Selling & Marketing (S&M) and General & Administrative (G&A) expenses rose 12.3% and 19.1%, respectively. Research & Development (R&D) expenses were up 33.4%.
Operating income improved 17.4% from the year-ago quarter to $199.4 million. Operating margin expanded 210 bps to 49%.
Balance Sheet & Cash Flow
Total cash and cash equivalents, as of Dec 31, 2019, were $1.51 billion compared with $881.2 million, as of Sep 30, 2019.
Total debt was $3.1 billion, as of Dec 31. Total debt to adjusted EBITDA ratio (based on trailing twelve months adjusted EBITDA) was 3.6x, which was higher than management’s target range of 3.0x-3.5x.
Net cash provided by operating activities was $243.6 million in fourth-quarter 2019 compared with $188.5 million in the previous quarter. Free cash flow was $225.2 million compared with $173.8 million in the prior quarter.
On Jan 29, MSCI declared a cash dividend of 68 cents per share for first-quarter 2020, payable on Mar 6 to shareholders of record as of Feb 21.
Guidance
For 2020, MSCI expects total operating expenses of $840-$860 million. Adjusted EBITDA expenses are expected between $750 million and $770 million.
Capex is expected to be $60-$70 million.
Moreover, net cash provided by operating activities and free cash flow is expected to be $650-$700 million and $580-$640 million, respectively.
While Perion is set to report quarterly results on Feb 3, both CEVA and Advanced Energy Industries are set to report on Feb 18.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
Image: Bigstock
MSCI Q4 Earnings Beat, Recurring Subscription Revenues Rise
MSCI Inc. (MSCI - Free Report) reported fourth-quarter 2019 adjusted earnings of $1.67 per share, which beat the Zacks Consensus Estimate by 2.5% and increased 27.5% from the year-ago quarter.
Operating revenues increased 12.4% year over year to $406.6 million, beating the consensus mark by 0.7%. The year-over-year growth was driven by an increase of 8.4% and 18.3% in recurring subscriptions (72.4% of revenues) and asset-based fees (23.7% of revenues), respectively.
Non-recurring revenues (3.9% of revenues) surged 83% year over year to $15.8 million. The solid growth was primarily driven by increased sales in BarraOne and RiskManager product offerings.
Organic operating revenues (excluding the impact of acquisitions, divestitures and foreign currency exchange rate fluctuations) rose 12.5% year over year.
Organic recurring subscription, asset-based fee and non-recurring revenues grew 8.5%, 18.3% and 82.3%, respectively.
At the end of the quarter, average assets under management (AUM) were $934.4 billion in ETFs linked to MSCI indexes. Total retention rate was 92.9% in the quarter.
MSCI Inc Price, Consensus and EPS Surprise
MSCI Inc price-consensus-eps-surprise-chart | MSCI Inc Quote
Index Revenue Details
In the fourth quarter, Index operating revenues (59.8% of operating revenues) improved 15.6% year over year to $243.2 million, primarily driven by strong growth in recurring subscriptions (up 11.5%) and asset-based fees (up 18.3%).
The increase in recurring subscriptions was driven by growth in factor and ESG index products, core developed market modules and index level products.
Index net new recurring subscription sales increased 14%.
Analytics Revenue Details
Analytics operating revenues (31.5% of operating revenues) improved 5.1% year over year to $128.2 million. While recurring subscription revenues increased 2.2%, non-recurring revenues jumped 162.5%. Multi-Asset Class Analytics products also witnessed growth in the quarter.
Analytics net new recurring subscription sales grew 50.1%.
All Other Segment Revenue Details
All Other operating revenues (8.7% of operating revenues) rose 20.1% from the year-ago quarter to $35.2 million, primarily driven by recurring subscriptions (up 20.8%).
All Other organic operating revenue growth was 19.9%, with ESG organic operating revenues increasing 29.8% and Real Estate organic operating revenues 1.3%.
All Other net new recurring subscription sales grew 33.7%.
Operating Details
Adjusted EBITDA grew 16% year over year to $220.2 million in the reported quarter. Moreover, adjusted EBITDA margin expanded 170 basis points (bps) on a year-over-year basis to 54.2%.
Total operating expenses increased 12.4% year over year to $406.6 million, primarily due to higher compensation and benefit costs.
Selling & Marketing (S&M) and General & Administrative (G&A) expenses rose 12.3% and 19.1%, respectively. Research & Development (R&D) expenses were up 33.4%.
Operating income improved 17.4% from the year-ago quarter to $199.4 million. Operating margin expanded 210 bps to 49%.
Balance Sheet & Cash Flow
Total cash and cash equivalents, as of Dec 31, 2019, were $1.51 billion compared with $881.2 million, as of Sep 30, 2019.
Total debt was $3.1 billion, as of Dec 31. Total debt to adjusted EBITDA ratio (based on trailing twelve months adjusted EBITDA) was 3.6x, which was higher than management’s target range of 3.0x-3.5x.
Net cash provided by operating activities was $243.6 million in fourth-quarter 2019 compared with $188.5 million in the previous quarter. Free cash flow was $225.2 million compared with $173.8 million in the prior quarter.
On Jan 29, MSCI declared a cash dividend of 68 cents per share for first-quarter 2020, payable on Mar 6 to shareholders of record as of Feb 21.
Guidance
For 2020, MSCI expects total operating expenses of $840-$860 million. Adjusted EBITDA expenses are expected between $750 million and $770 million.
Capex is expected to be $60-$70 million.
Moreover, net cash provided by operating activities and free cash flow is expected to be $650-$700 million and $580-$640 million, respectively.
Zacks Rank & Stocks to Consider
Currently, MSCI has a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader technology sector include Advanced Energy Industries (AEIS - Free Report) , Perion Network Ltd (PERI - Free Report) and CEVA, Inc. (CEVA - Free Report) , each sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
While Perion is set to report quarterly results on Feb 3, both CEVA and Advanced Energy Industries are set to report on Feb 18.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>